Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04496128 · ClinicalTrials.gov registry record

COVID19 Neurological Manifestation

A clinical trial, sponsored by University of Pittsburgh.

Completed
Registry status
300
Enrollment target

NCT04496128: Completed study, sponsored by University of Pittsburgh.

NCT04496128 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04496128 has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
300 participants
Enrollment target

Study Summary

This study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19).

Primary Outcome

Proportion of patients with neurological symptoms out of all hospitalized COVID19 patients during study period.

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2020-04-13
Est. Completion 2021-05-30
University of Pittsburgh

1,238 total trials

What the finished NCT04496128 record still lists

NCT04496128 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT04496128 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04496128 about?

NCT04496128 is a clinical study titled "COVID19 Neurological Manifestation". This study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19).

What is the current status of trial NCT04496128?

This trial is currently completed. The enrollment target is 300 participants. The study started on 2020-04-13. Estimated completion is 2021-05-30.

Who is sponsoring clinical trial NCT04496128?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04496128, the US trial registry maintained by the National Library of Medicine. NCT04496128 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.